L-ASPARAGINASA EFECTOS ADVERSOS PDF
Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.
|Published (Last):||5 January 2009|
|PDF File Size:||6.67 Mb|
|ePub File Size:||1.57 Mb|
|Price:||Free* [*Free Regsitration Required]|
Title of the trial for lay people, in easily understood, i. Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc. Subjects are under 18 years old. l-aspraginasa
l-asparaginasa efectos adversos pdf
Combination product that includes a device, but does not involve an Advanced Therapy. Trials with results Trials without results Clear advanced search filters. IMP with orphan designation in the indication. Relapsed or Refractory Acute Lymphoblastic Leukemia. Known allergy to any of the drugs used in the study.
Medicinas para Quimioterapia – Nombres de Medicina
Restricciones de tratamientos previos: Trials with results Trials without results. Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.
For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
The IMP has been designated in l-asparayinasa indication as an orphan drug in the Community. Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.
Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Review by the Competent Authority or Ethics Committee in the country concerned. Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7.
Active treatment for graft-versus-host disease 6. How to search [pdf]. Committee on Advanced therapies CAT has adversoz a classification for this product. Karnofsky or Lansky scores? Date on which this record was first entered in the EudraCT database:.
The trial involves single site in the Member State concerned. EU Clinical Trials Register.
Clinical Trials Register
A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. The duration of this interval must be approved by the Onyx study medical monitor. Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Clear advanced search filters. Adequate liver function, defined as both of the following: Subjects must have a serum creatinine level that is?
Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.
Pneumonia AND sponsor name. Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: For these items you should use the filters and not add them to your search terms in the text field.
Cancer AND drug name. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition. Age 18 years or younger at the time of study adbersos initiation.
Both Female Only Male Only. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy?